Drug General Information (ID: DDI9M7YTSR)
Drug Name			Metoclopramide		Drug Info		Alimemazine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiemetics				Antihistamines
Structure

Mechanism of Metoclopramide-Alimemazine Interaction (Severity Level: Major)
Additive antidopaminergic effects Click to Show/Hide Mechanism Graph
Drug Name		Metoclopramide				Alimemazine
Mechanism		Extrapyramidal effects				Extrapyramidal effects
Key Mechanism Factor 1
		Factor Name		Antidopaminergic effects
		Factor Description		Antidopamines are medications that inhibit or block the neurotransmitter activity of dopamine or related substances. Dopamine deficiency is associated with Parkinson's disease, restless legs syndrome and depression, and low dopamine levels can make you feel tired, moody, unmotivated and many other symptoms.
Mechanism Description		Additive antidopaminergic effects by the combination of Metoclopramide and Alimemazine

Recommended Action
Management		Due to the potential for increased risk of serious and potentially irreversible extrapyramidal reactions, metoclopramide should not be prescribed in combination with other antidopaminergic agents. In addition, metoclopramide should not be used for longer than 12 weeks except in rare cases where therapeutic benefit is anticipated to outweigh the risk of developing tardive dyskinesia.

References
1	Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993): 1469-75. [PMID: 8512437]
2	Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992): 983-5. [PMID: 1447672]
3	Stewart RB, Cerda JJ, Moore MT, Hale WE "Metoclopramide: an analysis of inappropriate long-term use in the elderly." Ann Pharmacother 26 (1992): 977-9. [PMID: 1504411]